etanercept products — Medica

Still’s Disease

Initial criteria

age > 18 years
Patient has tried one corticosteroid
Patient has tried one conventional synthetic DMARD for at least 2 months or was intolerant (example: methotrexate); a prior trial of one biologic other than the requested drug (e.g., Actemra, Arcalyst, Ilaris) also counts toward a trial of one other systemic agent for Still’s disease; a biosimilar of the requested biologic does not count
Medication is prescribed by or in consultation with a rheumatologist

Patient has been established on therapy for at least 6 months
When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (examples: resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers such as CRP or ESR, or reduced dosage of corticosteroids) OR patient experienced improvement in at least one symptom from baseline such as less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living

initial 6 months, reauth 1 year